— Know what they know.
Not Investment Advice

XENE NASDAQ

Xenon Pharmaceuticals Inc.
1W: -3.4% 1M: -4.5% 3M: +28.2% YTD: +21.6% 1Y: +72.2% 3Y: +31.6% 5Y: +212.1%
$54.17
+0.05 (+0.09%)
 
Weekly Expected Move ±4.4%
$50 $52 $54 $57 $59
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 35 · $4.3B mcap · 78M float · 1.80% daily turnover · Short 35% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
32.0 / 100
NoneWeakNarrowWide
Primary source: Switching Costs  ·  ROIC: -798.7%  ·  5Y Avg: -580.8%
Cost Advantage
23
Intangibles
25
Switching Cost
49
Network Effect
37
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. XENE has No discernible competitive edge (32.0/100). The business operates without significant structural advantages. The primary source of advantage is Switching Costs. Negative ROIC of -798.7% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$69
Low
$74
Avg Target
$78
High
Based on 2 analysts since May 7, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 22Hold: 0Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$83.18
Analysts11
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-10 Wells Fargo Benjamin Burnett $44 $69 +25 +22.3% $56.44
2026-05-08 Needham Serge Belanger Initiated $78 +37.9% $56.55
2026-03-10 Deutsche Bank Initiated $90 +48.5% $60.61
2026-03-09 RBC Capital $58 $80 +22 +27.5% $62.76
2026-03-09 Jefferies Andrew Tsai $65 $100 +35 +59.3% $62.76
2026-03-09 Guggenheim Yatin Suneja $49 $90 +41 +43.4% $62.76
2026-03-09 Morgan Stanley Initiated $97 +54.6% $62.76
2026-03-09 Stifel Nicolaus Paul Matteis $66 $89 +23 +44.5% $61.58
2026-03-09 Jefferies Andrew Tsai Initiated $65 +5.6% $61.56
2026-02-23 Wolfe Research Initiated $60 +40.4% $42.72
2026-02-10 Stifel Nicolaus Initiated $66 +55.6% $42.43
2025-11-04 RBC Capital $55 $58 +3 +46.3% $39.63
2025-11-04 Cantor Fitzgerald Josh Schimmer Initiated $55 +38.3% $39.78
2025-11-04 Wells Fargo Benjamin Burnett $50 $44 -6 +7.0% $41.12
2025-02-28 Wedbush $49 $42 -7 +13.5% $37.02
2024-10-10 Raymond James Danielle Brill $52 $50 -2 +26.8% $39.42
2024-10-01 H.C. Wainwright Douglas Tsao Initiated $53 +34.6% $39.37
2024-08-09 Wedbush Laura Chico $41 $49 +8 +19.4% $41.05
2024-06-18 RBC Capital Brian Abrahams $46 $55 +9 +51.7% $36.25
2022-12-14 Goldman Sachs Initiated $60 +51.6% $39.57
2022-11-28 Wells Fargo Initiated $50 +39.4% $35.86
2022-11-11 Guggenheim Initiated $49 +40.0% $35.00
2022-10-18 Raymond James Danielle Brill Initiated $52 +46.4% $35.52
2022-08-11 Leerink Partners Initiated $46 +15.9% $39.68
2022-08-10 RBC Capital $41 $46 +5 +13.5% $40.53
2022-06-27 Wedbush Initiated $41 +32.9% $30.85
2022-05-11 RBC Capital Initiated $41 +51.5% $27.07

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C+
May 22, 2026
DCF
3
ROE
1
ROA
1
D/E
4
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. XENE receives an overall rating of C+. Strongest factors: D/E (4/5). Areas of concern: ROE (1/5), ROA (1/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-05-18 C C+
2026-05-14 C+ C
2026-05-14 C C+
2026-05-08 C- C
2026-04-01 C C-
2026-03-02 C+ C
2026-02-27 C- C+
2026-02-26 C+ C-
2026-02-18 C C+
2026-02-09 C+ C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

Grade A+
Profitability
Balance Sheet
82
Earnings Quality
53
Growth
12
Value
29
Momentum
20
Safety
100
Cash Flow

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
5.13
Safe Zone
Piotroski F-Score
2/9
Beneish M-Score
Ohlson O-Score
-5.32
Bankruptcy prob: 0.5%
Low Risk
Credit Rating
A+
Score: 75.6/100
Trend: Stable
Earnings Quality
OCF/NI: 0.80x
Accruals: -8.6%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. XENE scores 5.13, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. XENE scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. XENE's implied 0.5% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. XENE receives an estimated rating of A+ (score: 75.6/100), with a stable trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-12.35x
PEG
0.36x
P/S
0.00x
P/B
3.54x
P/FCF
-16.53x
P/OCF
EV/EBITDA
-11.37x
EV/Revenue
EV/EBIT
-11.30x
EV/FCF
-14.77x
Earnings Yield
-7.54%
FCF Yield
-6.05%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. XENE currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.995
NI / EBT
×
Interest Burden
0.959
EBT / EBIT
×
EBIT Margin
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.332
Assets / Equity
=
ROE
-57.3%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. XENE's ROE of -57.3% is driven by A tax burden ratio of 0.99 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$54.17
Median 1Y
$58.13
5th Pctile
$21.46
95th Pctile
$157.66
Ann. Volatility
59.1%
Analyst Target
$83.18
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Ian Mortimer
President and Chief Executive Officer
$786,000 $1,774,000 $9,221,712
Thomas Kelly
$114,545 $1,257,000 $7,238,664
Darren Cline
$279,659 $— $4,048,214
Christopher Kenney
Chief Medical Officer
$565,000 $532,200 $3,145,290
Andrea DiFabio
Chief Legal Officer and Corporate Secretary
$510,000 $532,200 $3,062,790
Sherry Aulin
Former Chief Financial Officer
$330,441 $— $356,453

CEO Pay Ratio

1158:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $9,221,712
Avg Employee Cost (SGA/emp): $7,963
Employees: 10,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
10,000
+2958.1% YoY
Revenue / Employee
$750
Rev: $7,500,000
Profit / Employee
$-34,591
NI: $-345,910,000
SGA / Employee
$7,963
Avg labor cost proxy
R&D / Employee
$30,094
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -44.8% -49.9% -21.9% -23.0% -25.5% -31.5% -19.7% -23.2% -25.8% -27.5% -22.1% -22.9% -24.1% -25.9% -27.8% -29.9% -33.1% -36.4% -51.8% -57.3% -57.33%
ROA -35.1% -39.0% -20.7% -21.8% -24.1% -29.8% -18.9% -22.2% -24.7% -26.4% -21.2% -21.9% -23.2% -24.8% -26.6% -28.5% -31.6% -34.8% -38.9% -43.1% -43.06%
ROIC 20.8% 22.8% -9.6% -9.7% -10.7% -13.4% -73.0% -90.9% -1.1% -1.2% -56.2% -58.9% -62.4% -67.1% -1.6% -1.7% -1.8% -2.0% -7.2% -8.0% -7.99%
ROCE -34.7% -38.5% -14.2% -14.4% -15.8% -19.8% -17.1% -21.5% -24.9% -27.3% -22.8% -23.9% -25.3% -27.3% -36.6% -38.4% -41.7% -43.9% -38.5% -42.7% -42.72%
Gross Margin -7.3% -1.3% -4.9% -1.2% -40.3% -222.0% 1.0%
Operating Margin -10.1% -1.9% -6.6% -2.0% -56.6% -288.8% -9.7%
Net Margin -10.0% -1.9% -6.8% -2.2% -58.1% -281.4% -8.7%
EBITDA Margin -10.0% -1.9% -6.6% -1.9% -55.9% -286.1% -9.6%
FCF Margin -3.4% -3.2% -3.9% -3.0% -3.4% -6.7% -10.7% -178.6% -1039.7% -26.8% -30.9% -33.8% -37.3%
OCF Margin -3.2% -3.1% -3.8% -2.9% -3.4% -6.6% -10.4% -171.3% -990.7% -26.5% -30.7% -33.6% -37.2%
ROE 3Y Avg snapshot only -39.83%
ROE 5Y Avg snapshot only -31.00%
ROA 3Y Avg snapshot only -30.03%
ROIC 3Y Avg snapshot only -3.10%
ROIC Economic snapshot only -55.28%
Cash ROA snapshot only -31.21%
Cash ROIC snapshot only -7.51%
CROIC snapshot only -7.53%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -13.27 -9.84 -16.31 -20.25 -18.61 -20.81 -20.65 -15.96 -15.49 -12.88 -17.67 -17.71 -15.21 -14.38 -13.11 -10.50 -8.88 -10.39 -10.27 -13.26 -12.349
P/S Ratio 42.87 32.54 69.80 73.40 80.77 179.43 274.42 3521.39 19209.50 352.00 329.50 424.24 473.62 0.000
P/B Ratio 4.57 3.77 2.34 3.05 3.11 4.30 3.59 3.26 3.51 3.12 3.47 3.60 3.26 3.31 4.07 3.50 3.27 4.21 6.11 8.73 3.537
P/FCF -12.67 -10.05 -17.99 -24.27 -23.58 -26.84 -25.55 -19.72 -18.48 -15.04 -21.35 -20.79 -18.98 -18.44 -16.52 -13.11 -10.67 -12.56 -12.69 -16.53 -16.531
P/OCF
EV/EBITDA -10.21 -7.13 -9.52 -14.31 -13.42 -16.65 -16.24 -11.40 -10.83 -8.51 -12.33 -12.32 -10.27 -9.66 -8.87 -6.96 -5.87 -7.72 -8.38 -11.37 -11.373
EV/Revenue 33.37 23.79 40.32 49.61 55.09 138.17 212.77 2650.65 14803.04 269.61 247.11 341.86 401.49
EV/EBIT -10.08 -7.04 -9.41 -14.11 -13.23 -16.45 -16.03 -11.28 -10.72 -8.37 -12.13 -12.11 -10.11 -9.55 -8.79 -6.90 -5.83 -7.66 -8.32 -11.30 -11.303
EV/FCF -9.86 -7.35 -10.39 -16.41 -16.08 -20.66 -19.81 -14.84 -14.24 -11.16 -17.20 -16.88 -15.05 -14.67 -13.20 -10.04 -8.01 -10.12 -10.76 -14.77 -14.770
Earnings Yield -7.5% -10.2% -6.1% -4.9% -5.4% -4.8% -4.8% -6.3% -6.5% -7.8% -5.7% -5.6% -6.6% -7.0% -7.6% -9.5% -11.3% -9.6% -9.7% -7.5% -7.54%
FCF Yield -7.9% -9.9% -5.6% -4.1% -4.2% -3.7% -3.9% -5.1% -5.4% -6.6% -4.7% -4.8% -5.3% -5.4% -6.1% -7.6% -9.4% -8.0% -7.9% -6.0% -6.05%
PEG Ratio snapshot only 0.364
Price/Tangible Book snapshot only 8.731
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 12.30 12.30 39.03 39.03 39.03 39.03 26.44 26.44 26.44 26.44 23.65 23.65 23.65 23.65 17.85 17.85 17.85 17.85 13.42 13.42 13.415
Quick Ratio 12.30 12.30 39.03 39.03 39.03 39.03 26.44 26.44 26.44 26.44 23.65 23.65 23.65 23.65 17.85 17.85 17.85 17.85 13.42 13.42 13.415
Debt/Equity 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.014
Net Debt/Equity -1.01 -1.01 -0.99 -0.99 -0.99 -0.99 -0.81 -0.81 -0.81 -0.81 -0.68 -0.68 -0.68 -0.68 -0.82 -0.82 -0.82 -0.82 -0.93 -0.93 -0.930
Debt/Assets 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.008
Debt/EBITDA -0.06 -0.05 -0.11 -0.10 -0.10 -0.08 -0.08 -0.07 -0.06 -0.05 -0.05 -0.05 -0.05 -0.04 -0.03 -0.03 -0.03 -0.03 -0.02 -0.02 -0.020
Net Debt/EBITDA 2.91 2.62 6.96 6.86 6.26 4.97 4.70 3.74 3.22 2.96 2.98 2.85 2.68 2.48 2.23 2.13 1.96 1.86 1.51 1.36 1.356
Interest Coverage -3530.42 -4157.53 -4226.47 -4637.89
Equity Multiplier 1.10 1.10 1.04 1.04 1.04 1.04 1.05 1.05 1.05 1.05 1.04 1.04 1.04 1.04 1.06 1.06 1.06 1.06 1.69 1.69 1.687
Cash Ratio snapshot only 13.134
Cash to Debt snapshot only 69.094
FCF to Debt snapshot only -38.677
Defensive Interval snapshot only 600.7 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.11 0.12 0.05 0.06 0.06 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.000
Inventory Turnover
Receivables Turnover 13.87 15.07 8.04 9.96 9.23 5.74 5.03 0.36 0.07 0.00 0.00 0.00 0.00 0.00 0.00 6.40 6.40 6.40 5.28 0.00 0.000
Payables Turnover 18.01 24.86 21.98 22.87 23.97 27.04 11.52 8.38 4.78 0.00 0.00 0.07 0.07 0.07 0.09 0.00 0.09 11.37 17.49 17.49 17.487
DSO 26 24 45 37 40 64 73 1025 5186 57 57 57 69
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 20 15 17 16 15 13 32 44 76 5207 5207 5207 4164 3947 32 21 21 20.9 days
Cash Conversion Cycle 6 10 29 21 24 50 41 981 5110 -3890 25 48
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue -33.0% -34.6% -42.7% -22.4% 15.8% -33.6% -48.8% -97.1% -99.4% -1.0% -1.0% -1.0% -1.0% -1.0% -1.00%
Net Income -1.1% -1.4% -1.7% -1.2% -55.5% -73.0% -58.9% -78.1% -78.3% -54.2% -45.5% -27.9% -21.6% -21.9% -28.5% -33.3% -39.8% -43.6% -47.6% -52.4% -52.38%
EPS -75.9% -94.8% -1.4% -49.7% -16.5% -11.7% 0.3% -48.6% -52.1% -52.9% -36.5% -8.4% -3.1% -3.3% -14.7% -31.5% -37.5% -41.2% -46.0% -37.3% -37.28%
FCF -4.0% -2.5% -39.6% -17.8% -17.2% -37.0% -41.6% -72.7% -89.3% -70.2% -49.0% -34.7% -16.2% -11.0% -23.2% -25.3% -45.1% -52.2% -50.5% -52.6% -52.63%
EBITDA -1.3% -1.5% -1.7% -1.1% -45.5% -65.0% -58.3% -96.1% -1.1% -79.9% -70.3% -41.8% -29.5% -28.5% -31.5% -31.8% -35.0% -31.4% -29.9% -37.4% -37.42%
Op. Income -1.1% -1.2% -1.5% -1.0% -44.0% -65.0% -63.5% -1.0% -1.1% -84.1% -65.7% -39.3% -27.6% -25.4% -30.5% -30.8% -33.9% -33.4% -33.6% -40.8% -40.84%
OCF Growth snapshot only -54.43%
Asset Growth snapshot only 22.99%
Equity Growth snapshot only -22.94%
Debt Growth snapshot only -11.88%
Shares Change snapshot only 11.00%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y 3.0% 9.7% 45.4% 56.2% 52.2% 11.5% 11.4% -63.6% -83.1% -31.0% -29.2% -17.1% -7.4%
Revenue 5Y 16.5% 33.7% 59.2% 79.7% 91.6% 81.4% 97.9% 17.8% -14.0% -11.6% -22.8% -24.4% -25.3%
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y
Gross Profit 5Y -17.1%
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 60.1% 60.1% 67.2% 67.2% 67.2% 67.2% 72.2% 72.2% 72.2% 72.2% 72.1% 72.1% 72.1% 72.1% 11.7% 11.7% 11.7% 11.7% 9.2% 9.2% 9.19%
Assets 5Y 24.2% 24.2% 53.3% 53.3% 53.3% 53.3% 74.9% 74.9% 74.9% 74.9% 51.1% 51.1% 51.1% 51.1% 40.1% 40.1% 40.1% 40.1% 39.0% 39.0% 39.00%
Equity 3Y 68.3% 68.3% 74.6% 74.6% 74.6% 74.6% 98.7% 98.7% 98.7% 98.7% 75.6% 75.6% 75.6% 75.6% 11.1% 11.1% 11.1% 11.1% -6.9% -6.9% -6.92%
Book Value 3Y 17.5% 31.8% 49.3% 35.7% 34.7% 28.0% 58.2% 60.9% 60.8% 41.8% 37.0% 43.2% 43.2% -10.3% -1.5% -0.8% 4.3% -12.6% -15.3% -15.34%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.37 0.54 0.55 0.80 0.63 0.33 0.21 0.05 0.00 0.00 0.08 0.11 0.12 0.36 0.29 0.30 0.64 0.67 0.64 0.58 0.577
Earnings Stability 0.64 0.59 0.55 0.61 0.69 0.66 0.68 0.71 0.77 0.80 0.83 0.84 0.88 0.93 0.94 0.96 0.98 0.98 0.97 0.96 0.958
Margin Stability 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.44 0.52 0.00 0.00 0.00 0.00 0.00 0.000
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.82 0.89 0.91 0.91 0.89 0.87 0.84 0.83 0.81 0.50 0.500
Earnings Smoothness
ROE Trend 0.02 -0.04 0.17 0.16 0.16 0.14 -0.02 -0.02 0.03 0.05 -0.04 -0.03 -0.02 -0.01 -0.13 -0.13 -0.15 -0.17 -0.34 -0.39 -0.390
Gross Margin Trend -0.06 -1.69 -1.88 -2.26 -2.35 -5.32 -5.24 -74.96 -219.66
FCF Margin Trend 0.10 -1.23 -2.65 -1.65 -1.51 -4.77 -8.00 -176.09 -1036.32
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 1.00 0.94 0.88 0.81 0.77 0.76 0.79 0.78 0.80 0.81 0.80 0.83 0.79 0.77 0.78 0.79 0.83 0.82 0.81 0.80 0.800
FCF/OCF 1.05 1.04 1.03 1.03 1.02 1.02 1.03 1.04 1.05 1.05 1.04 1.02 1.02 1.01 1.02 1.01 1.01 1.01 1.00 1.00 1.003
FCF/Net Income snapshot only 0.802
CapEx/Revenue 16.3% 11.9% 11.1% 8.1% 7.1% 12.6% 30.7% 7.3% 49.1% 39.1% 21.0% 16.9% 10.7%
CapEx/Depreciation snapshot only 0.360
Accruals Ratio -0.00 -0.02 -0.02 -0.04 -0.05 -0.07 -0.04 -0.05 -0.05 -0.05 -0.04 -0.04 -0.05 -0.06 -0.06 -0.06 -0.05 -0.06 -0.08 -0.09 -0.086
Sloan Accruals snapshot only -0.094
Cash Flow Adequacy snapshot only -344.615
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -15.5% -19.1% -34.8% -20.1% -35.5% -25.5% -10.7% -11.5% 0.0% -1.3% -11.0% -10.6% -11.7% -10.6% -0.4% -0.5% -0.5% -0.4% -3.2% -18.8% -18.84%
Total Shareholder Return -15.5% -19.1% -34.8% -20.1% -35.5% -25.5% -10.7% -11.5% 0.0% -1.3% -11.0% -10.6% -11.7% -10.6% -0.4% -0.5% -0.5% -0.4% -3.2% -18.8% -18.84%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.69 1.58 1.00 1.00 3.10 2.20 1.99 1.75 1.00 1.01 1.00 1.00 1.00 1.00 0.98 0.98 0.98 0.99 1.00 0.99 0.995
Interest Burden (EBT/EBIT) 0.58 0.62 1.00 1.04 0.34 0.47 0.50 0.54 0.90 0.87 0.85 0.84 0.84 0.84 0.85 0.87 0.89 0.93 0.95 0.96 0.959
EBIT Margin -3.31 -3.38 -4.28 -3.52 -4.16 -8.40 -13.28 -234.94 -1380.65 -39.07 -42.42 -44.62 -48.25
Asset Turnover 0.11 0.12 0.05 0.06 0.06 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.000
Equity Multiplier 1.28 1.28 1.06 1.06 1.06 1.06 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.05 1.05 1.05 1.05 1.33 1.33 1.332
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-1.40 $-1.55 $-1.91 $-1.51 $-1.63 $-1.73 $-1.91 $-2.24 $-2.49 $-2.65 $-2.61 $-2.43 $-2.56 $-2.74 $-2.99 $-3.20 $-3.52 $-3.87 $-4.36 $-4.39 $-4.39
Book Value/Share $4.07 $4.05 $13.35 $10.03 $9.79 $8.40 $10.99 $10.98 $10.95 $10.93 $13.26 $11.96 $11.95 $11.91 $9.63 $9.59 $9.56 $9.53 $7.34 $6.66 $15.32
Tangible Book/Share $4.07 $4.05 $13.35 $10.03 $9.79 $8.40 $10.99 $10.98 $10.95 $10.93 $13.26 $11.96 $11.95 $11.91 $9.63 $9.59 $9.56 $9.53 $7.34 $6.66 $6.66
Revenue/Share $0.43 $0.47 $0.45 $0.42 $0.38 $0.20 $0.14 $0.01 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.10 $0.09 $0.09 $0.09 $0.00 $0.00
FCF/Share $-1.47 $-1.52 $-1.74 $-1.26 $-1.29 $-1.35 $-1.54 $-1.82 $-2.08 $-2.27 $-2.16 $-2.07 $-2.05 $-2.13 $-2.37 $-2.56 $-2.93 $-3.20 $-3.53 $-3.52 $-3.52
OCF/Share $-1.40 $-1.46 $-1.69 $-1.23 $-1.26 $-1.32 $-1.50 $-1.74 $-1.99 $-2.16 $-2.08 $-2.02 $-2.02 $-2.10 $-2.33 $-2.52 $-2.91 $-3.18 $-3.52 $-3.51 $-3.51
Cash/Share $4.21 $4.19 $13.39 $10.06 $9.82 $8.43 $9.02 $9.01 $8.99 $8.97 $9.12 $8.22 $8.22 $8.19 $8.00 $7.97 $7.94 $7.91 $6.93 $6.28 $12.53
EBITDA/Share $-1.42 $-1.57 $-1.90 $-1.44 $-1.55 $-1.67 $-1.88 $-2.36 $-2.74 $-2.98 $-3.01 $-2.84 $-3.01 $-3.24 $-3.53 $-3.69 $-4.00 $-4.19 $-4.53 $-4.57 $-4.57
Debt/Share $0.08 $0.08 $0.20 $0.15 $0.15 $0.13 $0.16 $0.16 $0.16 $0.16 $0.16 $0.14 $0.14 $0.14 $0.12 $0.11 $0.11 $0.11 $0.10 $0.09 $0.09
Net Debt/Share $-4.13 $-4.11 $-13.19 $-9.91 $-9.67 $-8.30 $-8.86 $-8.85 $-8.83 $-8.81 $-8.96 $-8.08 $-8.07 $-8.05 $-7.88 $-7.85 $-7.83 $-7.80 $-6.83 $-6.19 $-6.19
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 5.129
Altman Z-Prime snapshot only 9.919
Piotroski F-Score 3 3 3 4 4 4 2 2 2 2 2 2 2 2 1 2 2 2 3 2 2
Beneish M-Score 6.24 -2.22 -2.52 -1.30 0.23 61.66
Ohlson O-Score snapshot only -5.320
ROIC (Greenblatt) snapshot only -75.16%
Net-Net WC snapshot only $1.84
EVA snapshot only $-330083200.00
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only A+
Credit Score 74.02 61.06 61.06 61.83 63.30 75.48 76.78 76.20 76.41 76.48 76.71 76.44 76.56 76.30 76.29 76.25 76.42 76.04 64.25 75.61 75.608
Credit Grade snapshot only 5
Credit Trend snapshot only -0.641
Implied Spread (bps) snapshot only 125.000
Industry Credit Rank snapshot only 76
Sector Credit Rank snapshot only 70

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms